Haemonetics Corporation (HAE)
Chart Events
Performance Outlook
| Previous Close | 73.74 |
| Open | 73.25 |
| Bid | 73.36 x 900 |
| Ask | 73.52 x 900 |
| Day's Range | 73.10 - 74.15 |
| 52 Week Range | 43.50 - 79.45 |
| Volume | |
| Avg. Volume | 415,469 |
| Market Cap | 3.753B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 56.25 |
| EPS (TTM) | 1.30 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HAE
Related Research
- Haemonetics CorporationHAE: Lowering target price to $86.00HAEMONETICS CORP/MASS has an Investment Rating of BUY; a target price of $86.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat5 days agoArgus Research
- Zacks
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
- PR Newswire
Haemonetics Earns CE Mark for VASCADE® Vascular Closure Product Portfolio
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced it has earned CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous vascular closure systems. The CE marking will allow Haemonetics to engage in the next steps of country-specific entrance of both products into the European Union (EU) and forms the basis for entry into other geographies that recogni
- Zacks
Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
